ClinicalTrials.gg
RecruitingNCT07188155Updated Oct 20, 2026

Adapting Exposure for Adolescent AN

An interventional study of Exposure Therapy for Anorexia (Exp-AN) in Anorexia Nervosa, sponsored by Milton S. Hershey Medical Center. Recruiting at 1 site in United States. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Milton S. Hershey Medical Center · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Oct 20, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 174 studies in Anorexia Nervosa with a site in United States — 36 open to participants now, 45 under way, none of them phase 3. Anorexia Nervosa · United States.

Planned enrollment
121st of 143
16 · median 40
Started
2026
with 8 others
No phase
94 of 174
24 open now
Primary completion
2027-03
later than 18 of 44 live
Registered
165th of 174
by date

Among the 174 studies in Anorexia Nervosa with a site in United States, this one is the 121st largest by planned enrollment of the 143 interventional ones that give a count, is one of 9 that started in 2026, is one of 94 with no phase, reaches primary completion later than 18 of the 44 other live ones, and was the 165th registered.

Anorexia Nervosa

471 studies on the registry are indexed under Anorexia Nervosa; 127 are open to participants now.

Browse Anorexia Nervosa studies →

Open to participants now

36 of the 174 studies in Anorexia Nervosa with a site in United States are open now. Recruiting first, the newest first:

30 more — sign in →

All 36 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 82 Anorexia Nervosa studies recruiting now, 18 (22%) set no upper age limit and 60 (73%) stop at 75 or younger; 48 take children under 18; 26 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 174 studies in Anorexia Nervosa with a site in United States, or all of them as a file.
02

Study summary

This pilot study is evaluating Exposure Therapy (Exp-AN) as a virtual treatment for adolescents (ages 14 - 17 years) with anorexia nervosa (AN) recruited from eating disorder clinic waitlists and clinician referrals at the Penn State Milton S. Hershey Medical Center and the University of California, San Francisco (UCSF) (8 participants per site). Adolescents who agree to take part in this study will receive 20 free virtual 40-60 minute weekly Exp-AN sessions at an outpatient level of care. Exp-AN for adolescents will combine individual virtual session time (35-50 min) with parent involvement (10-25 min). Parents will serve as "collaborators," supporting skill development, exposure completion, and treatment goal achievement. Exp-AN sessions will focus on helping participants overcome anxiety about weight gain by encouraging them to do challenging things that increase anxiety in the short term but help them better tolerate anxiety over the long term. Participants will be asked to complete a clinical interview, questionnaires, and labs and vitals testing before they begin the study. Adolescents will also complete questionnaires and participate in 15-min semi-structured interviews, while parents/caregivers will complete separate parallel interviews, at: mid-treatment, end-of-treatment, and 3-month follow-up. To ensure that all participants are receiving the same type of therapy, they will not be able to have any concurrent psychotherapy while receiving this treatment (other forms of care including dieticians, nutritionists, and psychiatrists are allowed).

Exp-AN is designed to target anxiety about weight gain. Exp-AN includes education about the effects of undereating; the importance of overcoming anxiety about weight gain; in-session weight exposures (e.g., stepping on a scale while reading a script describing fears about weight gain); creating a meal plan to help improve eating; reviewing eating behaviors over the past week; conducting in-session and between-session exposures that help participants face fears related to weight gain; and relapse prevention.

03

Conditions studied

  • Anorexia Nervosa

Browse trials for

Keywords

  • anorexia nervosa
  • exposure therapy
  • adolescents
04

Who can participate

The criteria were revised on the registry on Oct 20, 2026. See what changed

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a diagnosis of anorexia nervosa (AN)
  • English speaking
  • Mentally stable for an outpatient level of care
  • Living with at least one parent/caregiver
  • Experienced significant weight loss as determined by the local principal investigator at each enrolling local site

Exclusion criteria

Exclusion Criteria:

  • Younger than 12 years old or older than 17 years old
  • Has a current psychotherapist and not open to pausing treatment for the duration of the study
  • Has a diagnosis of bulimia nervosa or binge-eating disorder
  • Acutely suicidal
  • Pregnant
  • Meets criteria for a psychotic disorder and/or has an intellectual disability
  • Non-English speaking
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    Exposure Therapy for AN (Exp-AN)

    Exp-AN aims to target anxiety about weight gain by helping participants identify their specific feared consequences of weight gain (e.g., "I will permanently hate myself if I gain weight"), and combining in vivo (i.e., in real life) and imaginal (i.e., mental) exposure exercises to address these fears. Exp-AN consists of four core modules: (1) Treatment Rationale and Psychoeducation; (2) In-Session Weight Exposure; (3) Planning, Conducting, and Reviewing Exposures; and (4) Relapse Prevention.

    Behavioral: Exposure Therapy for Anorexia (Exp-AN)

Interventions

  • BehavioralExposure Therapy for Anorexia (Exp-AN)

    Exp-AN is specifically designed to target anxiety about weight gain. Exp-AN helps participants identify their specific feared consequences of weight gain (e.g., "I will permanently hate myself if I gain weight"), and combines in vivo (i.e., in real life) and imaginal (i.e., mental) exposure exercises to address these fears.

06

What researchers measure

Primary outcomes

  1. Eating Disorder Examination - Self-Report Questionnaire (EDE-Q)

    The Eating Disorder Examination Questionnaire (EDE-Q) is a 28-item self-report questionnaire. It was designed to assess the range, frequency, and severity of behaviors associated with a diagnosis of an eating disorder. A global score is obtained by summing the four subscales scores (ranging from 0-6) and dividing the total by the number of subscales (4). The score of items are calculated and range from 0 to 6. The higher score indicate greater ED symptoms.

    Time frame: Baseline, Mid-Treatment, End-of-Treatment, 3-Month-Follow-Up

  2. Fear of Food Measure (FOFM)

    The Fear of Food Measure (FORM) is a 23-item self-report questionnaire. It examines the participant's severity of behaviors associated with a diagnosis of an eating disorder. Each item is scored on a 1-7 scale. The questionnaire range from 23 to 161 meaning 23: no fear of food and 161 meaning severe fear of food.

    Time frame: Baseline, Mid-Treatment, End-of-Treatment, 3-Month-Follow-Up

  3. Body Shape Questionnaire (BSQ)

    The BSQ is a self-reported measurement of the body shape concerns typical of bulimia nervosa and anorexia nervosa. The questionnaire has 34 items scored from 0 to 6 points (least and most impaired, respectively), with the sum of the questions giving a range from 0 to 204. The higher score indicates greater concerns about body shape.

    Time frame: Baseline, Mid-Treatment, End-of-Treatment, 3-Month-Follow-Up

  4. Clinical Impairment Assessment (CIA)

    The Clinical Impairment Assessment Questionnaire (CIA) is a 16-item self-report measure of the severity of psychosocial impairment due to eating disorder features and focuses on the past 28 days. The 16 items cover impairment in domains of life that are typically affected by eating disorder psychopathology: mood and self-perception, cognitive functioning, interpersonal functioning, and work performance. The responses are scored 0,1,2 and 3, with a higher rating indicating a higher level of impairment. The total range is between 0 and 48.

    Time frame: Baseline, Mid-Treatment, End-of-Treatment, 3-Month-Follow-Up

  5. Eating Disorder Fear Questionnaire (EDFQ)

    The Eating Disorder Fear Questionnaire (EDFQ) is a 20-item self-report questionnaire. It examines the participant's severity of behaviors associated with a diagnosis of an eating disorder. The response range between 1 to 7 with a total range of 20 to 140. The higher rating indicates a higher severe impairment.

    Time frame: Baseline, Sessions 1-20, 3-Month-Follow-Up

  6. Weight Gain Anxiety Questionnaire

    The Weight Gain Anxiety Questionnaire is a 12-item self-report questionnaire that targets anxiety about weight gain. The scores are measured on a 0-100 scale, with the higher the score indicating more distress about weight gain, with the exception for question 2 which is reverse scored.

    Time frame: Baseline, Sessions 1-20, 3-Month-Follow-Up

  7. Eating Anxiety Questionnaire

    The Eating Gain Anxiety Questionnaire is a 14-item self-report questionnaire that targets anxiety about eating fear foods. The scores are measured on a 0-100 scale, with the higher the score indicating more distress about eating fear foods, with the exception for question 2 which is reverse scored.

    Time frame: Baseline, Sessions 1-20, 3-Month-Follow-Up

  8. Patient Health Questionnaire-9 (PHQ-9)

    The Patient Health Questionnaire-9 is a 9-item self-report questionnaire that targets depressive symptoms. The scores range from 0-27, with higher scores indicating a higher level of depression.

    Time frame: Baseline, Mid-Treatment, End-of-Treatment, 3-Month-Follow-Up

  9. Generalized Anxiety Disorder-7 (GAD-7)

    The Generalized Anxiety Disorder-7 is a 7-item self-report questionnaire that targets anxiety symptoms. The scores range from 0 to 21, with higher scores indicating higher levels of anxiety.

    Time frame: Baseline, Mid-Treatment, End-of-Treatment, 3-Month-Follow-Up

  10. Eating Disorder Examination - Self-Report Questionnaire Parent Version 1.5 (PEDE-Q)

    Eating Disorder Examination - Self-Report Questionnaire Parent Version 1.5 (PEDE-Q) is a 29-item self-report questionnaire. It is intended to be completed by the parent of a child with an eating disorder targeting the parent's perspective of their child's eating disorder. It was designed to assess the range, frequency, and severity of behaviors associated with a diagnosis of an eating disorder. A global score is obtained by summing the four subscales scores (ranging from 0-6) and dividing the total by the number of subscales (4). The score of items are calculated and range from 0 to 6. The higher scores indicate greater perceived child's ED symptoms.

    Time frame: Baseline, Mid-Treatment, End-of-Treatment, 3-Month-Follow-Up

  11. Parent vs Eating Disorder Scale (PVED)

    The Parent vs Eating Disorder Scale (PVED) is a 7-item self-report questionnaire that examines parents' opinions on parent involvement in the treatment of their child's eating disorder. Higher scores indicate higher agreement with the statements, and lower scores indicate lower agreement with the statements. Scores range from 1 (strongly disagree) - 5 (strongly agree).

    Time frame: Baseline, Mid-Treatment, End-of-Treatment, 3-Month-Follow-Up

  12. Percent of Expected Body Weight (EBW)

    We will measure the participants' weight using a wireless smart scale.

    Time frame: Baseline, Mid-Treatment, End-of-Treatment, 3-Month-Follow-Up

Secondary outcomes

  1. Treatment Acceptability Questionnaire

    The Treatment Acceptability Questionnaire is a 10-item self-report questionnaire. It examines the participants' perspective on the modules in the exposure therapy. The response range between 1 to 7, with a total range of 10 to 70. The higher rating indicates a higher rating of treatment acceptability.

    Time frame: Baseline, Mid-Treatment, End-of-Treatment, 3-Month-Follow-Up

  2. Recruitment

    We will measure recruitment by calculating the percentage of eligible participants approached who consent to the study. The higher the percentage, the more successful we were with recruiting for the study.

    Time frame: Through study completion, an average of 2 years

  3. Retention

    We will measure the percent of participants who complete the study by calculating the percentage of participants that complete the three-month follow-up. The higher the percentage, the more participants completed the study.

    Time frame: Through study completion, an average of 2 years

  4. Engagement

    We will measure participant engagement by calculating the number of sessions participants attend out of 20 total sessions. The higher the number of sessions attended, the more participant engagement in the study.

    Time frame: Through study completion, an average of 2 years

  5. Treatment Fidelity

    We will measure the therapists' adherence to the protocol by completing a treatment adherence measure that measures the study interventionists' adherence to the protocol. The higher the treatment adherence measure, the more the study interventionists adhered to the protocol.

    Time frame: Through study completion, an average of 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Mar 2027, 13 months after the start.

Of 149 non-industry interventional studies with no phase under Anorexia Nervosa, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 63. This study's planned 13 months is below that.

Counting every sponsor, half of 149 studies reached it within 43 months; a quarter within 24 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2025
First posted
Sep 23, 2025
StartActual
Feb 20, 2026
Primary completionEst.
Mar 31, 2027
CompletionEst.
Jun 30, 2027
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
Minimum age 14 Years→12 Years; 1 inclusion criterion added, 1 removed; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • RemovedLess than or equal to 90% of expected body weight
  • AddedExperienced significant weight loss as determined by the local principal investigator at each enrolling local site
Exclusion criteria
  • EditedYounger than 1412 years old or older than 17 years old
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Eligibility Minimum age 14 Years→12 Years; 1 inclusion criterion added, 1 removed; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • RemovedLess than or equal to 90% of expected body weight
    • AddedExperienced significant weight loss as determined by the local principal investigator at each enrolling local site
    Exclusion criteria
    • EditedYounger than 1412 years old or older than 17 years old
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07188155
Responsible party
Jamal Essayli (Assistant Professor of Pediatrics and Psychiatry & Behavioral Health, Milton S. Hershey Medical Center) — Principal investigator
First posted
Sep 23, 2025
Start date
Feb 20, 2026
Primary completion
Mar 31, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Oct 20, 2026

Study contacts

Jamal Essayli, PhD
Contact
jessayli@pennstatehealth.psu.edu
(717) 531-0003 ext. 320191

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion